Skip to main content

Table 1 Patient characteristics and treatment details

From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Patient No

Sex

Age

ECOG PS

Recurrent/metastasis status

oligometastasis

Number of previous lines of therapy

1

M

28

2

Liver and multiple bone metastasis (thoracic and lumbar vertebra, pelvis, sternum, bilateral femur, bilateral ribs, right humerus)

No

2

2

M

52

0

Multiple liver metastasis

Yes

2

3

F

53

1

Local recurrence, multiple sites in liver, hilar lymph node, left scapula

Yes

1 (refused to receive chemotherapy)

4

M

44

1

Metastasis in liver and in right axillary lymph nodes

Yes

2

5

M

41

0

Multiple metastasis in liver and bone (lumbar vertebra)

 

PD within 6 months

6

M

56

1

Multiple metastasis (right 6th rib, right axillary lymph nodes and multiple lung nodules)

Yes

4

7

M

48

1

Regional refractory in bilateral neck; liver and multiple bone metastasis (sternum, thoracic and lumbar vertebra)

No

PD within 3 months

8

M

39

2

Local and regional relapse in nasopharynx and bilateral neck

NA

2

  1. F, female; M, male; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease